Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 105
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, et al.
Pharmacological Research (2022) Vol. 187, pp. 106597-106597
Open Access | Times Cited: 87
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis
Bo Xu, Mingxia Yang, Shaoqian Li, et al.
Annals of Pharmacotherapy (2025)
Closed Access | Times Cited: 2
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
Raffaele Marfella, Lucia Scisciola, Nunzia D’Onofrio, et al.
Pharmacological Research (2022) Vol. 184, pp. 106448-106448
Open Access | Times Cited: 68
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 53
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 29
Cardiovascular outcomes with SGLT-2 inhibitors in individuals with diabetes and co-existing atrial fibrillation: A systematic review and meta-analysis
Muhammad Zain Ameer, Muhammad Aemaz Ur Rehman, Zunaira Amjad, et al.
International Journal of Cardiology (2025), pp. 133083-133083
Closed Access | Times Cited: 1
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Global research trends on DPP-4 inhibitors and cardiovascular outcomes a comprehensive bibliometric analysis
Ehsan Amini‐Salehi, Maryam Hasanpour, Abdulhadi Alotaibi, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 4, pp. 2133-2148
Open Access
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
Gabriella di Mauro, Annamaria Mascolo, Mario Gaio, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 286-286
Open Access | Times Cited: 14
The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function
Sergey Shityakov, Michiaki Nagai, Süleyman Ergün, et al.
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1113-1113
Open Access | Times Cited: 14
Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
Bosung Shim, Jesse A. Stokum, Mitchell Moyer, et al.
Cells (2023) Vol. 12, Iss. 18, pp. 2221-2221
Open Access | Times Cited: 8
Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
Tobias Norre, Daniela Grimm, Ulf Simonsen
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 425-438
Open Access | Times Cited: 11
Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
Antonio González‐Pérez, David Vizcaya, María Eugenia Sáez, et al.
BMJ Open Diabetes Research & Care (2023) Vol. 11, Iss. 1, pp. e003072-e003072
Open Access | Times Cited: 6
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
William Hinton, Abdus Samad Ansari, Martin Whyte, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 501-515
Closed Access | Times Cited: 9
Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database
Annamaria Mascolo, Alessia Zinzi, Mario Gaio, et al.
Pharmacological Reports (2024)
Closed Access | Times Cited: 1
The pivotal role of miRNA-21 in myocardial metabolic flexibility in response to short- and long-term high glucose treatment: Evidence in human cardiomyocyte cell line
Lucia Scisciola, Rosaria Benedetti, Ugo Chianese, et al.
Diabetes Research and Clinical Practice (2022) Vol. 191, pp. 110066-110066
Open Access | Times Cited: 7
Real-world-Daten in der Arzneimittelregulation – aktuelle Entwicklungen und Ausblick
Julia Wicherski, Katharina Schneider, Jörg Zinserling, et al.
Prävention und Gesundheitsförderung (2023)
Open Access | Times Cited: 3
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation
Dongdong Wang, Yizhen Mao, Yang Yang, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 5
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In‐Wha Kim, Jung Mi Oh
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial
Sukanya Siriyotha, Thitiya Lukkunaprasit, Teeranan Angkananard, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 2
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
Annamaria Mascolo, Concetta Rafaniello, Gabriella di Mauro, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 2
Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021)
Wajd Alkabbani, John‐Michael Gamble
Canadian Journal of Diabetes (2022) Vol. 47, Iss. 2, pp. 153-161
Closed Access | Times Cited: 3


Urinary and Renal Research (2024) Vol. 5, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top